Stay updated with breaking news from Alpine Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MARKET WRAPS Stocks: European stocks traded mostly lower on Thursday ahead of the European Central Bank's interest rate decision. The ECB will probably leave interest rates unchanged ,... -April 11, 2024 at 06:02 am EDT - MarketScreener
A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston on Oct. 23, 2019. Vertex Pharmaceuticals will buy Alpine Immune Sciences…
RUBY-3 findings support povetacicept’s ability to induce remission, reduce UPCR, stabilize renal function, and resolve hematuria in patients with IgAN.
Fundamental data and tools for long term investing, research and analysis for U.S. stocks, economy and indexes.
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion in cash. Povetacicept, a potent dual antagonist of BAFF and APRIL, shows promise in IgA nephropathy. Transaction expected to close Q2 2024. VRTX expanding into kidney disease treatment.